Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings, with a GAAP net loss of $4.68M ($0.11 per share) vs. the expected $5.89M ($0.14 per share). Lower-than-expected R&D spending was a primary driver for the narrower loss. Operationally, the FDA's IND clearance for rexaceract (GT-02287) positions the company to initiate Phase 2 trials in Q3 2026, while cash reserves of $13.1M reflect a continued burn that necessitates ongoing capital management.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Gain Therapeutics(GANX) the EBIT is -4.682 M (+8.01%), Beat estimate;the EPS is -0.11 (+42.11%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.00B8.01%
-0.01B15.41%
+0.00B23.42%
EPSExceed expectations
-0.1142.11%
-0.137527.63%
+0.027514.48%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf